Phio Pharmaceuticals (PHIO) Company Report

Phio Pharmaceuticals Corp. announced that its Phase 1b clinical trial for PH-762 showed a 70% overall response rate for squamous cell carcinomas (cSCC), with 10 out of 14 responders achieving 100% clearance.
The trial also demonstrated favorable safety and tolerability across all dose escalations of PH-762.
A total of 22 patients with cutaneous carcinomas completed treatment across five cohorts in the Phase 1b trial, which evaluates PH-762 for the treatment of skin cancer.

Jan 20, 2026, 2:33 PM

Phio Pharmaceuticals announces FDA acceptance of PH-762 study design

PHIO

New Projects/Investments

Product Launch

Phio Pharmaceuticals Corp. announced that the FDA accepted its nonclinical protocol study design for PH-762, marking a significant advancement in its drug development program.
A toxicology study for PH-762 is scheduled to commence in the First Quarter 2026, which is a required step by the FDA before initiating a human pivotal trial.
The company is also progressing initiatives to deliver commercially viable PH-762 drug product in 2026, meeting FDA's current Good Manufacturing Practices, with recent financing directed towards these efforts.

Dec 23, 2025, 1:50 PM

Phio Pharmaceuticals Announces Completion of Enrollment in PH-762 Phase 1b Clinical Trial

PHIO

New Projects/Investments

Phio Pharmaceuticals Corp. has completed enrollment in its ongoing Phase 1b clinical trial for PH-762, an INTASYL siRNA lead compound designed to silence the PD-1 gene implicated in various forms of skin cancer.
The trial, which evaluated the safety and tolerability of intratumoral PH-762 in 18 patients with cutaneous carcinomas, reported six complete responses (100% clearance) among 16 cutaneous squamous cell carcinoma (cSCC) patients.
PH-762 has been well tolerated by all enrolled patients, with no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects observed to date. Pathology results for additional patients are expected in Q1 2026.

Nov 25, 2025, 9:12 PM

Phio Pharmaceuticals Reports Q3 2025 Financial Results and Positive Clinical Trial Data

PHIO

Earnings

Guidance Update

New Projects/Investments

Phio Pharmaceuticals Corp. reported a net loss of $2.4 million for the third quarter ended September 30, 2025, an increase from $1.5 million for the same period in 2024.
The company's cash and cash equivalents were approximately $10.7 million as of September 30, 2025, and an estimated $21.3 million as of November 13, 2025.
A warrant inducement financing in November 2025 is expected to generate approximately $12.1 million in net proceeds, which is projected to extend the company's cash runway into the first half of 2027.
The Phase 1b clinical trial for PH-762 has advanced to its fifth and final cohort, with positive pathology results at the maximum dose, including 100% tumor clearance in one patient.

Nov 13, 2025, 9:20 PM

Phio Pharmaceuticals Announces Exercise of Warrants

PHIO

Phio Pharmaceuticals Corp. announced the exercise of outstanding warrants, expected to generate approximately $13.4 million in gross proceeds.
This involves the purchase of 5,663,182 shares of common stock, with original warrant exercise prices ranging from $2.00 to $5.45 per share.
A significant portion of these warrants (4,654,586 shares) were exercised at a reduced price of $2.05 per share.
In consideration for the exercise, holders will receive new unregistered warrants to purchase up to 11,326,364 shares of common stock, with an exercise price of $2.05 per share and a twenty-four-month term.
The net proceeds are intended for working capital and to accelerate development activities for PH-762.

Nov 6, 2025, 9:11 PM

Phio Pharmaceuticals Announces Positive Pathology Results for PH-762 Skin Cancer Trial

PHIO

New Projects/Investments

Phio Pharmaceuticals Corp. reported positive pathology results for its lead drug candidate, PH-762, in the final maximum dose cohort of its Phase 1b skin cancer trial on November 3, 2025.
In the final cohort, one patient achieved 100% tumor clearance (Complete Response), another >90% clearance (Near Complete Response), and a third >50% clearance (Partial Response) for cutaneous squamous cell carcinoma (cSCC).
The Safety Monitoring Committee issued a favorable review of safety data, confirming no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects at the maximum dose or in any patients treated in the trial.
Cumulatively, six patients with cSCC have achieved a complete response (100% clearance) in the Phase 1b trial.